Much of his study explores Internal medicine relationship to Adverse effect. Borrowing concepts from Oncology, he weaves in ideas under Gastroenterology. Stefan Faderl undertakes multidisciplinary studies into Oncology and Gastroenterology in his work. While working in this field, he studies both Leukemia and Minimal residual disease. His study deals with a combination of Minimal residual disease and Leukemia. His Myeloid leukemia study frequently links to other fields, such as Immunology. In most of his Immunology studies, his work intersects topics such as Myeloid leukemia. He performs multidisciplinary studies into Gene and Genetics in his work. He integrates Genetics and Gene in his research.
His study in Biochemistry and Genetics is carried out as part of his Gene studies. His Biochemistry study frequently links to related topics such as Gene expression. He performs multidisciplinary study on Gene expression and DNA methylation in his works. Stefan Faderl incorporates Genetics and Gene in his research. Internal medicine and Adverse effect are commonly linked in his work. Stefan Faderl conducted interdisciplinary study in his works that combined Gastroenterology and Oncology. He conducted interdisciplinary study in his works that combined Oncology and Gastroenterology. He merges Leukemia with Chronic lymphocytic leukemia in his study. His research combines Cytarabine and Myeloid leukemia.
The study of Internal medicine is intertwined with the study of Toxicity in a number of ways. His work in Toxicity is not limited to one particular discipline; it also encompasses Internal medicine. He performs multidisciplinary study in Gastroenterology and Oncology in his work. By researching both Oncology and Gastroenterology, Stefan Faderl produces research that crosses academic boundaries. In his research, he undertakes multidisciplinary study on Leukemia and Neutropenia. In his articles, Stefan Faderl combines various disciplines, including Neutropenia and Leukemia. Myeloid leukemia is closely attributed to Imatinib in his research. Imatinib and Dasatinib are two areas of study in which he engages in interdisciplinary research. Many of his studies involve connections with topics such as Myeloid leukemia and Dasatinib.
Many of his studies on Internal medicine apply to Multivariate analysis as well. His Prednisone research extends to the thematically linked field of Gastroenterology. Prednisone is often connected to Gastroenterology in his work. In his articles, Stefan Faderl combines various disciplines, including Leukemia and Neutropenia. In his works, he undertakes multidisciplinary study on Neutropenia and Leukemia. Myeloid leukemia and White blood cell are two areas of study in which Stefan Faderl engages in interdisciplinary research. He merges White blood cell with Myeloid leukemia in his study. Many of his studies involve connections with topics such as Induction therapy and Chemotherapy. His Chemotherapy research extends to Induction therapy, which is thematically connected.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The biology of chronic myeloid leukemia
Stefan Faderl;Moshe Talpaz;Zeev Estrov;Susan O'Brien.
The New England Journal of Medicine (1999)
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner.
Journal of Clinical Oncology (2005)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian;Xavier G. Thomas;Anna Dmoszynska;Agnieszka Wierzbowska.
Journal of Clinical Oncology (2012)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Jean Pierre J. Issa;Guillermo Garcia-Manero;Francis J. Giles;Rajan Mannari.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang.
Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien.
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl.
Journal of Clinical Oncology (2005)
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos.
Chronic Myelogenous Leukemia: Biology and Therapy
Stefan Faderl;Moshe Talpaz;Zeev Estrov;Hagop M. Kantarjian.
Annals of Internal Medicine (1999)
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Guillermo Garcia-Manero;Hagop M. Kantarjian;Blanca Sanchez-Gonzalez;Hui Yang.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: